BIOMAT Database Logo BIOMAT Database Logo

Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer. 1999

R V Iaffaioli, and A Tortoriello, and G Facchini, and F Caponigro, and M Gentile, and N Marzano, and A Gravina, and P Dimitri, and G Costagliola, and A Ferraro, and G Ferrante, and V De Marino, and A Illiano
Cattedra di Oncologia Medica, Università di Cagliari, Italy.

OBJECTIVE Platinum-based chemotherapy currently represents standard treatment for advanced non-small-cell lung cancer. Gemcitabine is one of the most interesting agents currently in use in advanced non-small-cell lung cancer, and high response rates have been reported when it is administered in combination with cisplatin. The aim of the present study was to evaluate the combination of gemcitabine and carboplatin in a phase I-II study. METHODS Chemotherapy-naive patients with stage IIIB-IV non-small-cell lung cancer received carboplatin at area under the concentration-time curve (AUC) 5 mg/mL/min and gemcitabine at an initial dose of 800 mg/m2, subsequently escalated by 100 mg/m2 per step. Gemcitabine was administered on days 1 and 8 and carboplatin on day 8 of the 28-day cycle. Dose escalation proceeded up to dose-limiting toxicity (DLT), which was defined as grade 4 neutropenia or thrombocytopenia or grade 3 nonhematologic toxicity. RESULTS Neutropenia was DLT, inasmuch as it occurred in three of five patients receiving gemcitabine 1,200 mg/m2. Nonhematologic toxicities were mild. Gemcitabine 1,100 mg/m2 plus carboplatin AUC 5 was recommended for phase II studies. An objective response was observed in 13 (50%) of 26 patients, including four complete responses (15%) and nine partial responses (35%). Median duration of response was 13 months (range, 3 to 23 months). Median overall survival was 16 months (range, 3 to 26 months). CONCLUSIONS The combination of gemcitabine and carboplatin is well tolerated and active. Neutropenia was DLT. The observed activity matches that observable in cisplatin-gemcitabine studies, whereas duration of response and survival are even higher. A phase II trial is under way.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009325 Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D009503 Neutropenia A decrease in the number of NEUTROPHILS found in the blood. Neutropenias
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D003841 Deoxycytidine A nucleoside component of DNA composed of CYTOSINE and DEOXYRIBOSE. Cytosine Deoxyribonucleoside,Cytosine Deoxyriboside,Deoxyribonucleoside, Cytosine,Deoxyriboside, Cytosine
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration

Related Publications

R V Iaffaioli, and A Tortoriello, and G Facchini, and F Caponigro, and M Gentile, and N Marzano, and A Gravina, and P Dimitri, and G Costagliola, and A Ferraro, and G Ferrante, and V De Marino, and A Illiano
Phase II study of vinorelbine and gemcitabine for inoperable stage IIIB-IV non-small-cell lung cancer.
September 1999, Annals of oncology : official journal of the European Society for Medical Oncology,
R V Iaffaioli, and A Tortoriello, and G Facchini, and F Caponigro, and M Gentile, and N Marzano, and A Gravina, and P Dimitri, and G Costagliola, and A Ferraro, and G Ferrante, and V De Marino, and A Illiano
A phase II study of oxaliplatin and gemcitabine in advanced inoperable stage IIIB/IV non-small cell lung cancer.
June 2008, Clinical oncology (Royal College of Radiologists (Great Britain)),
R V Iaffaioli, and A Tortoriello, and G Facchini, and F Caponigro, and M Gentile, and N Marzano, and A Gravina, and P Dimitri, and G Costagliola, and A Ferraro, and G Ferrante, and V De Marino, and A Illiano
Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial.
September 2003, Lung cancer (Amsterdam, Netherlands),
R V Iaffaioli, and A Tortoriello, and G Facchini, and F Caponigro, and M Gentile, and N Marzano, and A Gravina, and P Dimitri, and G Costagliola, and A Ferraro, and G Ferrante, and V De Marino, and A Illiano
Randomized phase II study of two schedules of carboplatin and gemcitabine for stage IIIB and IV advanced non-small cell lung cancer (JACCRO LC-01 study).
January 2011, Chemotherapy,
R V Iaffaioli, and A Tortoriello, and G Facchini, and F Caponigro, and M Gentile, and N Marzano, and A Gravina, and P Dimitri, and G Costagliola, and A Ferraro, and G Ferrante, and V De Marino, and A Illiano
[Phase II clinical trial on gemcitabine in the treatment of stage IIIB-IV non-small cell lung cancer].
November 2003, Zhonghua zhong liu za zhi [Chinese journal of oncology],
R V Iaffaioli, and A Tortoriello, and G Facchini, and F Caponigro, and M Gentile, and N Marzano, and A Gravina, and P Dimitri, and G Costagliola, and A Ferraro, and G Ferrante, and V De Marino, and A Illiano
A phase I/II study comparing regimen schedules of gemcitabine and docetaxel in Japanese patients with stage IIIB/IV non-small cell lung cancer.
April 2005, Japanese journal of clinical oncology,
R V Iaffaioli, and A Tortoriello, and G Facchini, and F Caponigro, and M Gentile, and N Marzano, and A Gravina, and P Dimitri, and G Costagliola, and A Ferraro, and G Ferrante, and V De Marino, and A Illiano
Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer.
June 2000, Annals of oncology : official journal of the European Society for Medical Oncology,
R V Iaffaioli, and A Tortoriello, and G Facchini, and F Caponigro, and M Gentile, and N Marzano, and A Gravina, and P Dimitri, and G Costagliola, and A Ferraro, and G Ferrante, and V De Marino, and A Illiano
Prospective phase II study of single-agent gemcitabine in untreated elderly patients with stage IIIB/IV non-small-cell lung cancer.
December 2001, American journal of clinical oncology,
R V Iaffaioli, and A Tortoriello, and G Facchini, and F Caponigro, and M Gentile, and N Marzano, and A Gravina, and P Dimitri, and G Costagliola, and A Ferraro, and G Ferrante, and V De Marino, and A Illiano
Phase II study of Taxol combined With ifosfamide and carboplatin in the treatment of stage IIIb-IV non-small-cell lung cancer.
February 2003, American journal of clinical oncology,
R V Iaffaioli, and A Tortoriello, and G Facchini, and F Caponigro, and M Gentile, and N Marzano, and A Gravina, and P Dimitri, and G Costagliola, and A Ferraro, and G Ferrante, and V De Marino, and A Illiano
Phase I/II study of vinorelbine, mitomycin, and cisplatin for stage IIIB or IV non-small-cell lung cancer.
October 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Copied contents to your clipboard!